Original Article | Published:

Antitumor Pharmacology

Dihydroartemisinin is an inhibitor of ovarian cancer cell growth

Acta Pharmacologica Sinica volume 28, pages 10451056 (2007) | Download Citation

This work was supported by grants from the National Natural Science Foundation of China (No 30128018), the Natural Science Foundation of Jiangsu Province (No 03KJA180121), the Medical Development Foundation of Soo-chow University (No EE126506), and USA NIH (No ES013199).

Abstract

Aim:

To investigate the anticancer activity of dihydroartemisinin (DHA), a derivative of antimalaria drug artemisinin in a panel of human ovarian cancer cell lines.

Methods:

Cell growth was determined by the MTT viability assay. Apoptosis and cell cycle progression were evaluated by a DNA fragmentation gel electro-phoresis, flow cytometry assay, and TUNEL assay; protein and mRNA expression were analyzed by Western blotting and RT-PCR assay.

Results:

Artemisinin and its derivatives, including artesunate, arteether, artemether, arteannuin, and DHA, exhibit anticancer growth activities in human ovarian cancer cells. Among them, DHA is the most effective in inhibiting cell growth. Ovarian cancer cell lines are more sensitive (5-10-fold) to DHA treatment compared to normal ovarian cell lines. DHA at micromolar dose levels exhibits a dose- and time-dependent cytotoxicity in ovarian cancer cell lines. Furthermore, DHA induced apoptosis and G2 cell cycle arrest, accompanied by a decrease of Bcl-XL and Bcl-2 and an increase of Bax and Bad.

Conclusion:

The promising results show for the first time that DHA inhibits the growth of human ovarian cancer cells. The selective inhibition of ovarian cancer cell growth, apoptosis induction, and G2 arrest provide in vitro evidence for further studies of DHA as a possible anticancer drug in the clinical treatment of ovarian cancer.

References

  1. 1.

    , , , , , et al. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecol Oncol 2005; 98: 360–8.

  2. 2.

    , , . Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer. Gynecol Oncol 2007; 105: 166–71.

  3. 3.

    , , . Mechanisms of transcoelomic metastasis in ovarian cancer, Lancet Oncol 2006; 7: 925–34.

  4. 4.

    , , , , , et al. Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. Head Neck 2007; 29: 335–40.

  5. 5.

    , , , , , et al. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 2004; 68: 2359–66.

  6. 6.

    , , . Artemisinin induces apoptosis in human cancer cells. Anticancer Res 2004; 24: 2277–80.

  7. 7.

    , . Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer Cells. Life Sci 2001; 70: 49–56.

  8. 8.

    , , . mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, afrteether, and artemether. Biochem Pharmacol 2002; 64: 617–23.

  9. 9.

    , , . Artemisinin: an alternative treatment for oral squamous cell carcinoma. Anticancer Res 2004; 24: 2153–60.

  10. 10.

    , , . Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro, Pharmacol Res 2003; 48: 231–6.

  11. 11.

    , . Anti-tumor activity of artemisinin and its derivatives. J Guangzhou Univ TRadit Chin Med 2005; 22: 75–7. Chinese.

  12. 12.

    . Studies on artemisinin and its derivatives. Guangxi Med J 2003; 25: 1950–9. Chinese.

  13. 13.

    , , . The in vitro anti-tumor effect of four artemisinic acid and artesunate B derivatives. Acta Pharmacol Sin 1992; 13: 541–3. Chinese.

  14. 14.

    , , . The anti-tumor activity of sodium artesunate. Chin J Cancer 1997; 16: 186–9. Chinese.

  15. 15.

    , , , , . Comparison of inhibitory effects between artemisinin and artemisunate on proliferation of MCF-7 cells in vitro. Chin Tradit Herb Drugs 2003; 4: 347–9. Chinese.

  16. 16.

    , , , . Primary study of effect of hypoxic killing and radiation sensitivity of artemisinin on human cervical cancer cell. Chin J Cancer 2001; 20: 1363–6. Chinese.

  17. 17.

    , , , , . Apoptosis induced by artermisinin in K562 cells. Bull Chin Cancer 2003; 12: 473–5. Chinese.

  18. 18.

    , . Induction of human tumor cell apoptosis by sodium artesunate and its molecular mechanism. Chin Tradit Herb Drugs 2002; 33: 819–21. Chinese.

  19. 19.

    , , , , . The anticancer effect of artesunate and its mechanism. Acta Pharm Sin 2002; 37: 477–8. Chinese.

  20. 20.

    , , , . Effect of dihydroartemisinin on the proliferation of MCF-7 cell. Chin J New Drugs 2002; 11: 934–6. Chinese.

  21. 21.

    , , , , , . In vitro effect of artemisinin on human leukemia cells and primary cells. Chin J Intern Med 2003; 42: 713–4. Chinese.

  22. 22.

    , , . Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. J Med Chem 2004; 47: 1299–302.

  23. 23.

    . Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets 2006; 7: 407–21.

  24. 24.

    , , , , . Current perspectives on the mechanism of action of artemisinins. Int J Parasitol 2006; 36: 1427–41.

  25. 25.

    , , , , , et al. Dihydroartemisinin enhances radiosensitivity of human glioma cells In vitro. J Cancer Res Clin Oncol 2006; 132: 129–35.

  26. 26.

    , , , . Antiangiogenic activity of deoxoartemisinin derivatives on chorioallantoic membrane. Bioorg Med Chem Lett 2006; 16: 1227–30.

  27. 27.

    , , , , , et al. The multisubstrate adapter Gabl regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair. Mol Cell Biol 2001; 21: 4968–84.

  28. 28.

    , , , , , et al. Role of NF-KappaB signaling in heptocyte growth factor/scatter factor-mediated cell protection. Oncogene 2005; 24: 1749–66.

  29. 29.

    , , . Surfing the p53 network. Nature 2000; 408: 307–10.

  30. 30.

    , , , , , et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54: 5824–30.

  31. 31.

    . The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003; 22: 7486–95.

  32. 32.

    , . The p 53 protein family and radiation sensitivity: Yes or no? Cancer Metastasis Rev 2004; 23: 237–57.

  33. 33.

    . p53, the cellular gatekeeper for growth and divison. Cell 1997; 88: 323–31.

  34. 34.

    , , . The p53 tumour suppressor gene. Nature 1991; 351: 453–6.

  35. 35.

    , , , , . Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med 2006; 12: 382–93.

  36. 36.

    , , . Anti-cancer drugs: molecular mechanisms of action. Mini Rev Med Chem 2005; 5: 685–95.

  37. 37.

    . BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ 2006; 13: 1339–50.

  38. 38.

    , . Life-or-death decisions by the Bcl-2 protein familoy. Trends Biochem Sci 2001; 26: 61–6.

  39. 39.

    , . BCL2 familoy of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006; 43: 1–67.

  40. 40.

    . Recent advances in understanding the celll death pathways activated by anticancer therapy. Cancer 2005; 103: 1551–60.

Download references

Author information

Affiliations

  1. School of Radiology and Public Health, Soochow University, Suzhou 215123, China

    • Yang Jiao
    • , Jian-ping Cao
    • , Jian Tong
    •  & Sai-jun Fan
  2. Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC 20057, USA

    • Chun-min Ge
    • , Qing-hui Meng
    •  & Sai-jun Fan

Authors

  1. Search for Yang Jiao in:

  2. Search for Chun-min Ge in:

  3. Search for Qing-hui Meng in:

  4. Search for Jian-ping Cao in:

  5. Search for Jian Tong in:

  6. Search for Sai-jun Fan in:

Corresponding author

Correspondence to Sai-jun Fan.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1111/j.1745-7254.2007.00612.x

Further reading